NeuBase Therapeutics
Pittsburgh
About NeuBase Therapeutics
NeuBase Therapeutics is a pre-clinical stage biopharmaceutical company that develops gene silencing therapies with its synthetic antisense oligonucleotides. It also provides a platform that focuses on the development of drugs for rare genetic diseases such as Huntington's Disease, Myotonic Dystrophy, and Familial Parkinson's Disease, among others.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Public
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $14.0M
- Funding stage: IPO
- Last round: Post-IPO Equity (Jun 2023)
- Ticker: nasdaq:NBSE
- Website: neubasetherapeutics.com
- Phone: [email protected]
Industries & Categories
Biotechnology, Medical, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/neubase-therapeutics-138265 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.